Retatrutide Phase 3: Unprecedented Weight Loss and Glycemic Control
Key Questions
What is retatrutide and how does it differ from existing GLP-1 therapies?
Retatrutide is the first triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 3 data show it delivers up to 28.3% weight loss and 2.0% A1C reduction in obesity and type 2 diabetes, exceeding results seen with current GLP-1 agents.
What glycemic and weight-loss outcomes were reported in the retatrutide Phase 3 trials?
Adults with inadequately controlled type 2 diabetes achieved substantial HbA1c reductions alongside the noted weight loss. The data were presented at ADA 2026 and highlight superior glycemic control compared with existing therapies.
Does retatrutide provide benefits beyond weight loss and blood sugar control?
Yes, the trials also showed improvements in knee osteoarthritis pain and obstructive sleep apnea. These additional effects suggest retatrutide could broaden treatment options for obesity-related comorbidities.
Phase 3 data for retatrutide, the first triple agonist (GIP/GLP-1/glucagon), shows up to 28.3% weight loss and 2.0% A1C reduction in obesity and T2D. Also improves knee OA pain and sleep apnea. Could reshape obesity and diabetes treatment beyond current GLP-1s.